MORF Stock Overview
A biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Morphic Holding, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$30.77 |
52 Week High | US$63.08 |
52 Week Low | US$19.35 |
Beta | 1.48 |
1 Month Change | 7.51% |
3 Month Change | -13.30% |
1 Year Change | -49.56% |
3 Year Change | -52.65% |
5 Year Change | n/a |
Change since IPO | 70.94% |
Recent News & Updates
Recent updates
We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 20Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth
Sep 29We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow
Jun 07What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Feb 15We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 03What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Nov 08Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M
Aug 03Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)
May 06Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)
Mar 01Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Feb 17We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn
Nov 03Morphic: Pioneering Integrin Medicines
Oct 13Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business
Aug 05Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth
Apr 05Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)
Mar 09Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?
Feb 24How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?
Jan 20Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth
Dec 16Shareholder Returns
MORF | US Biotechs | US Market | |
---|---|---|---|
7D | 0.4% | 3.0% | 0.8% |
1Y | -49.6% | 8.3% | 22.5% |
Return vs Industry: MORF underperformed the US Biotechs industry which returned 8.3% over the past year.
Return vs Market: MORF underperformed the US Market which returned 22.5% over the past year.
Price Volatility
MORF volatility | |
---|---|
MORF Average Weekly Movement | 8.3% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MORF has not had significant price volatility in the past 3 months.
Volatility Over Time: MORF's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 124 | Praveen Tipirneni | www.morphictx.com |
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company’s products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive.
Morphic Holding, Inc. Fundamentals Summary
MORF fundamental statistics | |
---|---|
Market cap | US$1.54b |
Earnings (TTM) | -US$161.25m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs MORF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MORF income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$152.38m |
Gross Profit | -US$152.38m |
Other Expenses | US$8.88m |
Earnings | -US$161.25m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.22 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did MORF perform over the long term?
See historical performance and comparison